RxNow

Company NameProduct NameArchive typesAnnouncementView PDFDIN #
Pharmasciencepms-SOLIFENACINProduct Availability | Disponibilité des produitsWe are pleased to announce the back in stock of the following products: pms-SOLIFENACIN 5mg 30`s & 100`s & 10mg 100`s2417723
Pharmasciencepms-SOFLAX 100mg CAPS 100Discontinuation | Abandon de produitAfter careful consideration of our product portfolio, the decision has been made to cease production of SOFLAX 100mg CAPS 100 for the Canadian market effective immediately. Thes product will be removed from our product catalogue. 1994344
Pharmasciencepms-DOCUSATE SODIUM 100mg CAPS 100Discontinuation | Abandon de produitAfter careful consideration of our product portfolio, the decision has been made to cease production of pms-DOCUSATE SODIUM 100mg CAPS 100 for the Canadian market effective immediately. Thes product will be removed from our product catalogue. Please accept our sincere apologies for any inconvenience that this may cause.703494
Pharmasciencepms-QUINAPRIL 10-20mg 100Product Availability | Disponibilité des produitsPharmascience Canada is please to announced that pms-QUINAPRIL 10MG & 20MG TABS 100 are now back in stock and you may place your order now02340569
Pharmasciencepms-LEVODOPA CARBIDOPANew Product | Nouveau produitWe are pleased to announce the launch of pms-LEVODOPA CARBIDOPA IR!02549719
Pharmasciencepms-FLUTICASONE HFA 50mcgProduct Availability | Disponibilité des produitsWe are pleased to announce that pms-FLUTICASONE 50mcg is NOW AVAILABLE!02503115
Pharmasciencepms-RIVAROXABAN 15mg TABS 3500New pack size | Nouveau formatPharmascience Canada is please to announced the launch of a new large format for the following product: pms-RIVAROXABAN 15mg TABS 3500, you may place your order now.2512068
Pharmascience pms-NITROFURANTOIN BID 100mg CAPS 100Product Availability | Disponibilité des produitsPharmascience Canada is proud to announce that pms-NITROFURANTOIN BID 100mg CAPS 100 are back in stock and now available to order.2455676
SandozSandoz Enalapril & Sandoz RisperidoneDiscontinuation | Abandon de produitSandoz Canada wishes to inform you that the Sandoz Enalapril and Sandoz Risperidone will be no longer available upon depletion of inventory.00000
Pharmasciencepms-DOXYLAMINE PYRIDOXINE 10/10mg T 500Product Availability | Disponibilité des produitsPharmascience Canada is proud to announce that pms-DOXYLAMINE PYRIDOXINE 10/10mg T 500 are back in stock and now available to order. 2406187
Pharmasciencepms-AMLODIPINE 2.5mg TABS 500New pack size | Nouveau formatPharmascience Canada is please to announced the launch of a new large format for the following product: pms-AMLODIPINE 2.5mg TABS 500, you may place your order now.2295148
PharmascienceOLESTYR REG PWD ORANG FLV POUCH 30X4gProduct Availability | Disponibilité des produitsPharmascience Canada is proud to announce that OLESTYR REG PWD ORANG FLV POUCH 30X4g are back in stock and now available to order.02210320
Pharmasciencepms-VALACYCLOVIR 500mg CAPS 500New Product | Nouveau produitHello all, We are pleased to announce the launch of our 24th XL Format product, pms-VALACYCLOVIR 500mg CAPS 500. 02298457
PharmascienceRUPATADINENew Product | Nouveau produitPharmascience is pleased to announce the launch of pms-RUPATADINE!02552604
PharmascienceOctasa 800mgProduct Availability | Disponibilité des produitsLower the pill burden for your patients suffering from ulcerative colitis with OCTASA® 800 mg 02465752
SandozZolmitriptan FCT and Zolmitriptan ODTProduct Availability | Disponibilité des produitsSandoz Canada wishes to inform you that the following products will be unavailable for an indefinite period of time upon depletion of inventory.
Pharmasciencepms-SitagliptinNew Product | Nouveau produitWe are pleased to announce the launch of pms-SITAGLIPTIN!02503840
SandozRivastigmine capsulesDiscontinuation | Abandon de produitSandoz Canada wishes to inform you that Sandoz Rivastigmine capsules will be no longer available upon depletion of inventory. 00000
PharmascienceDuloxetine 30mg 1000 CAPSNew pack size | Nouveau formatPharmascience Canada is please to announced the launch of a new large format for the following products: pms-DULOXETINE 30mg CAPS 1000, you may place your order now.2429446
PharmasciencePalbociclib New Product | Nouveau produitNew product launch of pms-Palbociclib.02552132
Pharmascience pms-DULOXETINE 60mg CAPS 500 New pack size | Nouveau formatPharmascience Canada is please to announced the launch of a new large format for the following product: pms-DULOXETINE 60mg CAPS 500, you may place your order now.2429454
SandozAlendronate, Dimethyl Fumarate, Finasteride Discontinuation | Abandon de produitSandoz Canada wishes to inform you that the following products will be no longer available upon depletion of inventory.0000000
Pharmasciencepms-DAPAGLIFLOZINProduct Appearance Up date | Nouvel aspect du produitWe would like to inform you of the change in appearance of pms-DAPAGLIFOZIN 5MG & 10MG. Please take a few minutes to review the information below.02531550
SandozSandoz BilastineNew Product | Nouveau produitWe are glad to share the launch of PrSandoz® Bilastine02536269
SandozPr SANDOZ® FESOTERODINE FUMARATEProduct Availability | Disponibilité des produitsSandoz Canada wishes to inform you that the following product Pr SANDOZ® FESOTERODINE FUMARATE 8 MG 100 TABLETS will be unavailable for an indefinite period of time. Rest assured; we are doing our utmost to ensure the continuity of supply of the replacement product Pr Sandoz® Fesoterodine fumarate 8mg in bottles of 30 tablets.02521776
PharmasciencePERIOSTATProduct Transition | Transition dans la productionWe are pleased to announce the commercial transfer of PERIOSTAT 20mg Capsules from Pendopharm to Pharmascience Canada effective October 15th, 2024.02247104
SandozSandoz AFAtinibNew Product | Nouveau produitWe are glad to share the launch of PrSandoz® AFAtinib.02512777
Pharmasciencepms-GABAPENTIN 100mg CAPS 1000New pack size | Nouveau formatPharmascience Canada is please to announced the launch of a new large format for the following product: pms-GABAPENTIN 100mg CAPS 1000, you may place your order now. 02243446
PharmasciencePMS-AMLODIPINENew pack size | Nouveau formatPharmascience Canada is please to announced the launch of a new large format for the following products: pms-AMLODIPINE 5mg TABS 2000 / 10mg TABS 1000, you may place your order now.2284065
PharmascienceNone Selected
PharmasciencePMS-CLONAZEPAM-RProduct Transition | Transition dans la productionDear Customer, Pharmascience is pleased to announce the product change of PMS-CLONAZEPAM to PMS-CLONAZEPAM-R.02048701
Pharmasciencepms-Escitalopram 10mgProduct Availability | Disponibilité des produitsWe would like to inform you that we are currently experiencing difficulties in guaranteeing the supply of pms-Escitalopram 10mg blisters. Consequently we will be out of stock for an extended period of time02469243
Pharmasciencepms-ROSUVASTATIN 20mg TABS 1500New pack size | Nouveau formatDear Customer, Pharmascience Canada is pleased to announce the launch of a new large format for the following product: pms-ROSUVASTATIN 20mg TABS 1500.02378558
SandozMultiple ProductsDiscontinuation | Abandon de produitDiscontinuation Notice Multiple products
PharmascienceNew pack size | Nouveau formatDear Customer, Pharmascience Canada is please to announced the relaunch of the following products: pms-DEFERASIROX (TYPE J) 90mg, 180mg and 360mg TABS 30 BTL, are now available and you may place your order now.2528290
SandozPrSandoz® DutasterideNew Product | Nouveau produitWe’re glad to share the return of PrSandoz® Dutasteride 0.5 mg available in blister packs of 30 and bottles of 100 capsules. 02424444
SandozSandoz® DesvenlafaxineNew Product | Nouveau produitWe’re glad to share the launch of Sandoz® Desvenlafaxine.02538415
SandozSandoz Rivastigmine PatchInformation Update | Mise à jour des renseignementsSandoz Canada wishes to inform you that a downloadable tool is available for your patients who take Sandoz® Rivastigmine Patch. The tool is a multiple-page digital patient diary (one page per week) that can be printed out. It contains instructions for administering PrSandoz® Rivastigmine Patch and a place to record their use. 02426293
SandozSandoz® BisoprololNew Product | Nouveau produitSandoz® Bisoprolol new strengths. We're glad to share the launch of Sandoz® Bisoprolol 1.25 mg and 2.5 mg. • NEW CONCENTRATIONS exclusive to Sandoz 1.25 mg and 2.5 mg. • Scored tablets in 2.5 mg, 5 mg and 10 mg strengths. • Concentrations clearly indicated on tablets. • All strengths available in bottles of 100 tablets. 02544245
SandozSandoz LisdexamfetamineNew Product | Nouveau produitWe are glad to share the launch of Sandoz® Lisdexamfetamine.02546248
Pharmasciencepms-TRAZODONENew pack size | Nouveau formatPharmascience Canada is please to announced the launch of a new large format for the following product: pms-TRAZODONE 50mg TABS 1500, you may place your order now.01937227
SandozSandoz® Gliclazide MR and Sandoz® PravastatinDiscontinuation | Abandon de produitDiscontinuation Notice Sandoz Canada wishes to inform you that we are discontinuing Sandoz® Gliclazide MR and Sandoz® Pravastatin. The products will be no longer available upon depletion of inventory (date communicated below is subjected to change). Please accept our apologies for any inconvenience this may cause. 02461323
SandozSandoz Docusate SodiumDiscontinuation | Abandon de produitDiscontinuation Notice Sandoz® Docusate Sodium
Pharmasciencepms-PERINDOPRIL 8mgNew pack size | Nouveau formatPharmascience Canada is pleased to announce the launch of a new large format for the following product: pms-PERINDOPRIL 8mg TABS 1000.02470691
Pharmasciencepms-FLUOXETINE 20mg CAPSNew pack size | Nouveau formatPharmascience Canada is pleased to announce the launch of a new large format for the following product: pms-FLUOXETINE 20MG CAPS 1000 and is now available to order.02177587
PharmasciencePERICHLOR 0.12% ORAL RINSEImportant Announcement | Annonce importanteEffective June 1st, 2024, the following products will be transferred from Pendopharm, division of Pharmascience Inc. to Pharmascience Inc.02493160
PharmascienceNone Selected
SandozNone Selected
Pharmasciencepms-ROSUVASTATIN 5mg TABS 3000New pack size | Nouveau formatPharmascience Canada is pleased to announce the launch of a new large format for the following product: pms-ROSUVASTATIN 5mg TABS 3000.02378523
SandozSandoz Gliclazide MRProduct Availability | Disponibilité des produitsSee PDF02314177
SandozNYPOZINew Product | Nouveau produitNYPOZI (filgrastim) is now available! 02520990
SandozNYPOZI - ZIEXTENZONew Product | Nouveau produitNow offering the complete G-CSF portfolio 02520990
PharmascienceNone Selected
Pharmasciencepms-DICLOFENAC 1.5% SOL TOPI 60 mLProduct Availability | Disponibilité des produitsWe would like to inform you that we are currently experiencing difficulties in guaranteeing the supply of pms-DICLOFENAC 1.5% SOL TOPI 60 mL. Consequently we will be out of stock for an extended period of time.02356783
Pharmasciencepms-METHOTREXATE 50MG/MLNew Product | Nouveau produitPharmascience Canada is pleased to announce the launch of pms-METHOTREXATE 50MG/ML, you may place your order now.2539608
Pharmasciencepms-PERINDOPRIL-AMLODIPINENew Product | Nouveau produitPharmascience Canada is pleased to announce the launch of pms-PERINDOPRIL-AMLODIPINE, you may place your order now.02541696
Pharmasciencepms-CITALOPRAM HBR 40mg TAB 1100,New pack size | Nouveau formatPharmascience Canada is please to announced the launch of a new large format for the following product: pms-CITALOPRAM HBR 40mg TAB 1100, you may place your order now.02248011
SandozSandoz ApremilastNew pack size | Nouveau formatSandoz Apremilast Started Kit now available02529092
SandozSandoz OmeprazoleDiscontinuation | Abandon de produitDiscontinuation Notice Sandoz® Omeprazole 10 mg02296438
Pharmasciencepms-PREGABALIN 150mg 800New pack size | Nouveau formatDear Customer, Pharmascience Canada is pleased to announce the launch of a new large format for the following product: pms-PREGABALIN 150mg CAPS 800 and you may place your order now.2359634
Pharmasciencepms-LACTULOSE-PHARMA 667mg/mLProduct Transition | Transition dans la productionDear Customer, Pharmascience is pleased to announce the product change of pharma-LACTULOSE 667mg/mL 500mL to pms-LACTULOSE-PHARMA 667mg/mL 500mL and 1000mL, effective immediately.02247383
Pharmasciencepms-QUINAPRIL 40mg TABS 100Product Availability | Disponibilité des produitsDear client, Pharmascience Canada is pleased to announce that pms-QUINAPRIL 40mg TABS 100 is now back in stock and you may place your order now.02340585
PharmascienceSILDENAFIL 100mg Product Transition | Transition dans la productionPharmascience is pleased to announce the product change of SILDENAFIL 100mg TABS 30 to SILDENAFIL 100mg TABS BLI 1X 4, effective immediately.02317583
Pharmasciencepms-TERAZOSIN 2mg TABS 100Product Appearance Up date | Nouvel aspect du produitDear Customer, We would like to inform you of the change in appearance of pms-TERAZOSIN 2mg tablets. This change is effective immediately. Please take a few minutes to review the information below. 02243519
Pharmasciencepms-LITHIUM CARBONATE 300mg CAPS 100Product Availability | Disponibilité des produitsDear Customer, We would like to inform you that we are currently experiencing difficulties in guaranteeing the supply of pms-LITHIUM CARBONATE 300mg CAPS 100. Consequently we will be out of stock for an extended period of time.02216140

Author Agreement

In submitting your work (the “Work”) for potential posting on the MDBriefCase Healthcare Leadership Academy website (the “Website”), you (“You”) expressly agree to the following:

Review: MDBriefCase is pleased to consider the publication of Your Work on the Website.   The suitability of the Work for posting shall be determined by MDBRiefCase at its sole discretion. Nothing herein shall obligate MDBriefcase to post or otherwise publish the Work, or the maintain its posting in future.   

Editing; Identification: MDBriefcase shall have the right to edit the Work to conform to our standards of style, technological requirements, language usage, grammar and punctuation, provided that the meaning of the Work is not materially altered.  If posted, You will be identified as the author of the Work, or co-author if applicable.  

Grant of Rights:  As a condition of publication and for no monetary compensation, You hereby grant to MDBriefCase the following rights to the Work in any and all media whether now existing or hereafter developed, including print and electronic/digital formats:  (1) the exclusive right of first publication worldwide;  (2) the perpetual non-exclusive worldwide right to publish, reproduce, distribute, sell, adapt, perform, display, sublicense, and create derivative works, alone or in conjunction with other materials; (3) the perpetual non-exclusive worldwide right to use the Work, or any part thereof, in any other publication produced by MDBriefCase and/or on MDBriefCase’s website; and (4) the perpetual non-exclusive worldwide right to use the Work to promote and publicize MDBriefCase or its publications.  The grant of rights survives termination or expiration of this Agreement.    

Warranty:  You warrant that the Work is original with You and that it is not subject to any third party copyright; that You have authority to grant the rights in this Agreement; that publication of the Work will not libel anyone or infringe on or invade the rights of others; that You have full power and authority to enter into this Agreement; that the Work has not been published elsewhere in whole or in part; and that You have obtained permission from the copyright owner consistent with this Agreement for any third party copyrighted material in the Work.  This warranty survives termination or expiration of this Agreement.

Submission Agreement

Thank you for your interest in writing an article for the MDBriefCase Healthcare Leadership Academy website.

Audience and Appropriate Topics

The  Healthcare Leadership Academy welcomes submissions on all topics relevant to leaders in healthcare. Our topics include Leading in Healthcare, Leadership Lessons from COVID-19 and others. We prioritize stories that provide leadership advice to executives and managers in healthcare companies, offer actionable strategies for executing successful projects, and provide interesting angles on current healthcare topics. Submissions must be original work of the authors and unpublished.  When submitting, authors represent that they have included no material that is in violation of the rights of any other person or entity.

Parameters

Articles must be educational and non-promotional. If they mention the author’s company or any of the company’s products or services by name within the text, such mention should be very limited and used for reference only, not for promotion. (For example, an author might cite a survey conducted by his company but not describe his company’s product as a solution to a business problem.) Articles will be edited for clarity, style and brevity. The final headline is determined by the editor.

Length of Submissions

Guest articles for the MDBriefCase Healthcare Leadership Academy may run between 500 and 1000 words. 

Review

MDBriefCase reserves the right to accept or reject any submission  and the right to condition acceptance upon revision of material to conform to its criteria.   

No Compensation

There is no payment for contributed articles. However, MDBriefCase will give the author a byline. Authors are invited to link to the article on personal  websites, corporate websites and social media platforms.

Author Agreements

Each author understands and agrees that any submission accepted for posting is provided subject to MDBriefCase’s Author Agreement

mdbriefcase-logo
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful. Our cookie policy is available here.